Selling technology into the pharmaceutical and life sciences sector isn’t just about showing a better product; it’s about surviving a regulatory gauntlet. Decision-making isn’t owned by one person but by a fragmented committee of R&D heads, regulatory affairs officers, clinical operations managers, and IT security leads. Each stakeholder has a different veto power, and a single concern about data integrity or HIPAA compliance can stall a deal for eighteen months.
The sales cycle in this industry is notoriously long, often mirroring the drug development timelines themselves. Traditional broad-based marketing fails because it cannot address the specific therapeutic focus or the unique regulatory hurdles of a Tier-1 pharmaceutical firm. When your marketing is generic, you aren’t seen as a partner; you’re seen as a risk.
We replace the “spray and pray” approach with a surgical ABM framework that treats every high-value pharmaceutical account as its own market. We don’t just find leads; we map the entire decision-making ecosystem within accounts like Pfizer, Novartis, or Thermo Fisher. By identifying the specific pain points of each stakeholder—from the scientist’s need for data accuracy to the CFO’s demand for ROI—we build a consensus that moves deals forward.
Our approach centers on deep research and scientific credibility. We help you create content that speaks the language of clinical trials and regulatory submissions, ensuring your brand is positioned as a safe, compliant, and essential part of their infrastructure. We focus on the accounts that represent 80% of your potential revenue, ensuring your sales team spends their time on SQLs that actually close.
Smarketers’ inbound and ABM strategy for Josh Software, drives brand presence, organic traffic, and lead generation, yielding remarkable ROI.
How The Smarketers Built a Multi-Channel ABM Program for a Fortune 100 Technology Leader in India.
